DSP-6952, a novel 5-HT4 receptor partial agonist, inhibits visceral hypersensitivity and ameliorates gastrointestinal dysfunction in experimental animals

被引:10
作者
Mine, Yukiko [1 ]
Itakura, Tomohiro [1 ]
Oku, Seiko [1 ]
Asada, Reiko [1 ]
Shimizu, Isao [1 ]
机构
[1] Sumitomo Dainippon Pharma Co Ltd, Drug Res Div, Konohana Ku, 3-1-98 Kasugade Naka, Osaka 5540022, Japan
关键词
5-HT4 receptor agonist; Gastrointestinal motility; Visceral hypersensitivity; Gastroprokinetic; Irritable bowel syndrome; Constipation; IRRITABLE-BOWEL-SYNDROME; CHLORIDE CHANNEL ACTIVATOR; CHRONIC CONSTIPATION; PROPULSIVE MOTILITY; DOUBLE-BLIND; LUBIPROSTONE; SEROTONIN; ARTICLE; TRANSIT; PAPAVERINE;
D O I
10.1016/j.ejphar.2018.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacological profile of DSP-6952, a novel 5-HT4 receptor partial agonist, was investigated to evaluate the potential use for GI disorders, and to compare its effects in some GI dysfunction models with those of clinically efficacious prokinetic agents. DSP-6952 enhanced gastric motility and caused colonic giant migrating contractions (GMCs) associated with defecation in conscious dogs, having ED50 value for inducing GMCs of 1.56 mg/kg. DSP-6952 (3-10 mg/kg, i.g.) significantly enhanced colonic transit rate in guinea pigs; this enhancement was antagonized by SB-207266, a selective 5-HT4 receptor antagonist. DSP-6952 (1-10 mg/kg, p.o.) rapidly increased fecal wet weight without increasing fluid content in mice. Sennoside (30-100 mg/kg, p.o.) also increased fecal wet weight; however, it significantly increased fluid content with diarrhea. DSP-6952 dose-dependently improved clonidine-and morphine-induced delay in whole-gut transit in mice (ED50 = 0.429 mg/kg and 0.310 mg/kg, respectively), which represented atonic and spastic constipation models, respectively. In viscerally hypersensitive rats treated with acetic acid, DSP-6952 (10 mg/kg, i.p., 30 mg/kg, p.o., 30 mg/kg, i.c.) and tegaserod (1 mg/kg, i.p.), but not prucalopride (10 mg/kg, i.p.), significantly inhibited the increase in colorectal distension-induced visceromotor response; these findings suggest that DSP-6952 and tegaserod inhibit visceral hypersensitivity in rats. It was concluded that DSP-6952, a novel and orally available 5-HT4 receptor agonist, induced colonic GMCs, enhanced colonic transit, increased defecation without inducing diarrhea, improved drug-induced delay in whole-gut transit, and inhibited visceral hypersensitivity in experimental animals. Therefore, DSP-6952 is expected to become a useful drug for treatment of IBS-C and chronic constipation.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 39 条
  • [1] Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome
    Andresen, Viola
    Camilleri, Michael
    Busciglio, Irene A.
    Grudell, April
    Burton, Duane
    Mckinzie, Sanna
    Foxx-Orenstein, Amy
    Kurtz, Caroline B.
    Sharma, Vineeta
    Johnston, Jeffrey M.
    Currie, Mark G.
    Zinsmeister, Alan R.
    [J]. GASTROENTEROLOGY, 2007, 133 (03) : 761 - 768
  • [2] Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit
    Appel, S
    Kumle, A
    Meier, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) : 546 - 555
  • [3] Visceral perception: inflammatory and non-inflammatory mediators
    Bueno, L
    Fioramonti, J
    [J]. GUT, 2002, 51 : I19 - I23
  • [4] Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study
    Camilleri, M.
    Beyens, G.
    Kerstens, R.
    Robinson, P.
    Vandeplassche, L.
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (12) : 1256 - 1263+e117
  • [5] Review article: tegaserod
    Camilleri, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (03) : 277 - 289
  • [6] CISAPRIDE STIMULATES PROPULSIVE MOTILITY PATTERNS IN HUMAN JEJUNUM
    COREMANS, G
    JANSSENS, J
    VANTRAPPEN, G
    CHAUSSADE, S
    CECCATELLI, P
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1988, 33 (12) : 1512 - 1519
  • [7] Role of serotonin in the pathophysiology of the irritable bowel syndrome
    Crowell, MD
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (08) : 1285 - 1293
  • [8] Pharmacological management of constipation
    Emmanuel, A. V.
    Tack, J.
    Quigley, E. M.
    Talley, N. J.
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 : 41 - 54
  • [9] Prucalopride: A Review in Chronic Idiopathic Constipation
    Garnock-Jones, Karly P.
    [J]. DRUGS, 2016, 76 (01) : 99 - 110
  • [10] The serotonin signaling system: From basic understanding to drug development-for functional GI disorders
    Gershon, Michael D.
    Tack, Jan
    [J]. GASTROENTEROLOGY, 2007, 132 (01) : 397 - 414